BCDA
Price
$2.12
Change
+$0.04 (+1.92%)
Updated
Jul 3 closing price
Capitalization
10.98M
GNFT
Price
$3.87
Change
-$0.02 (-0.51%)
Updated
Jul 3 closing price
Capitalization
196.8M
78 days until earnings call
Interact to see
Advertisement

BCDA vs GNFT

Header iconBCDA vs GNFT Comparison
Open Charts BCDA vs GNFTBanner chart's image
BioCardia
Price$2.12
Change+$0.04 (+1.92%)
Volume$3.04M
Capitalization10.98M
Genfit SA
Price$3.87
Change-$0.02 (-0.51%)
Volume$330
Capitalization196.8M
BCDA vs GNFT Comparison Chart in %
Loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNFT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCDA vs. GNFT commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a Hold and GNFT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (BCDA: $2.12 vs. GNFT: $3.87)
Brand notoriety: BCDA and GNFT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 2176% vs. GNFT: 5%
Market capitalization -- BCDA: $10.98M vs. GNFT: $195.88M
BCDA [@Biotechnology] is valued at $10.98M. GNFT’s [@Biotechnology] market capitalization is $195.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileGNFT’s FA Score has 1 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • GNFT’s FA Score: 1 green, 4 red.
According to our system of comparison, GNFT is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 5 TA indicator(s) are bullish while GNFT’s TA Score has 5 bullish TA indicator(s).

  • BCDA’s TA Score: 5 bullish, 3 bearish.
  • GNFT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BCDA is a better buy in the short-term than GNFT.

Price Growth

BCDA (@Biotechnology) experienced а -4.93% price change this week, while GNFT (@Biotechnology) price change was +0.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

GNFT is expected to report earnings on Sep 22, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNFT($197M) has a higher market cap than BCDA($11M). GNFT YTD gains are higher at: 4.172 vs. BCDA (-2.752).
BCDAGNFTBCDA / GNFT
Capitalization11M197M6%
EBITDA-8.39MN/A-
Gain YTD-2.7524.172-66%
P/E RatioN/A109.28-
Revenue3KN/A-
Total Cash949KN/A-
Total Debt850KN/A-
FUNDAMENTALS RATINGS
BCDA vs GNFT: Fundamental Ratings
BCDA
GNFT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6261
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNFT's Valuation (83) in the Biotechnology industry is in the same range as BCDA (91) in the null industry. This means that GNFT’s stock grew similarly to BCDA’s over the last 12 months.

GNFT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that GNFT’s stock grew similarly to BCDA’s over the last 12 months.

GNFT's SMR Rating (97) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that GNFT’s stock grew similarly to BCDA’s over the last 12 months.

GNFT's Price Growth Rating (61) in the Biotechnology industry is in the same range as BCDA (62) in the null industry. This means that GNFT’s stock grew similarly to BCDA’s over the last 12 months.

GNFT's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for BCDA (100) in the null industry. This means that GNFT’s stock grew significantly faster than BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDAGNFT
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
64%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
85%
MACD
ODDS (%)
Bearish Trend 4 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 5 days ago
71%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
73%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNFT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EBR7.580.14
+1.88%
Centrais Eletricas Brasileiras SA- Eletrobras
TKLF3.730.03
+0.87%
Tokyo Lifestyle Co Ltd
BRLS3.630.03
+0.83%
Borealis Foods
CALM102.90-0.27
-0.26%
Cal-Maine Foods
CCRN13.01-0.08
-0.61%
Cross Country Healthcare

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been closely correlated with RNAC. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCDA jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
+1.73%
RNAC - BCDA
85%
Closely correlated
-1.41%
CDTX - BCDA
85%
Closely correlated
+1.90%
AGEN - BCDA
85%
Closely correlated
+10.16%
NBY - BCDA
84%
Closely correlated
+0.62%
WINT - BCDA
84%
Closely correlated
+20.68%
More

GNFT and

Correlation & Price change

A.I.dvisor tells us that GNFT and BCDA have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GNFT and BCDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNFT
1D Price
Change %
GNFT100%
-0.51%
BCDA - GNFT
26%
Poorly correlated
+1.73%
QURE - GNFT
24%
Poorly correlated
+0.98%
FENC - GNFT
24%
Poorly correlated
+3.04%
GLPG - GNFT
23%
Poorly correlated
+0.98%
GUTS - GNFT
23%
Poorly correlated
+0.61%
More